Another recent randomized trial [20] of 118 patients with MRI-proven NAFLD over 72 weeks demonstrated that pemafibrate treatment improved ALT, GGT, and ALP levels as well as cirrhosis. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.